PT-141 Benefits: What the Human Trials Show

PT-141 benefits are best supported for two outcomes in a specific group: improved self-reported sexual desire and less distress about low desire in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Early small studies in men also recorded stronger erectile responses, but those trials were physiological experiments—not evidence for a broad libido or sexual-performance claim.

PT-141 is the development name for bremelanotide. The receptor biology matters, but it is separate from the clinical evidence; how PT-141 works covers that mechanism in depth.

PT-141 benefits in the RECONNECT trials

The strongest evidence comes from RECONNECT 301 and 302, two identically designed phase 3 trials. Together, they randomized 1,267 premenopausal women with acquired, generalized HSDD; 1,202 were included in the efficacy analysis. Participants used subcutaneous bremelanotide or placebo as needed during 24 weeks.

The trials had two co-primary endpoints: change in the Female Sexual Function Index desire-domain score and change in a Female Sexual Distress Scale item asking how bothered a participant felt by low desire. The 2019 RECONNECT report in Obstetrics & Gynecology found statistically significant differences favoring bremelanotide on both measures.

These are average changes on validated questionnaires, not a promise that every participant felt a benefit. The study population was also narrow: the mean age was 39, 85.6% of participants were White, and every participant was premenopausal and met the trial definition of HSDD.

What “benefit” meant in those studies

The cleanest answer is more desire and less distress—not more sexual events. That distinction is easy to lose when PT-141 is described simply as a libido peptide. In RECONNECT, the satisfying-event count was a secondary endpoint and did not differ significantly from placebo. A post hoc analysis found that a larger share of encounters was rated satisfying, but post hoc findings are exploratory rather than the result the trial was designed to confirm.

HSDD also means more than a temporary change in interest. In the trials and label, it referred to low desire that caused marked distress or interpersonal difficulty, had developed after a period without desire problems, occurred across partners and situations, and was not better explained by a medical or psychiatric condition, relationship problems, or a medication. The evidence therefore does not automatically transfer to every reason someone might experience low libido.

What the early studies in men found

The male data answer a different question. A 2004 intranasal PT-141 trial by Diamond and colleagues studied healthy men and men with mild-to-moderate erectile dysfunction. RigiScan monitoring found a statistically significant erectile response versus placebo at doses above 7 mg, with the first erection beginning in about 30 minutes. This was an instrument-recorded physiological endpoint, not a measure of lasting improvement in desire or relationships.

A separate 2004 study by Rosen and colleagues tested subcutaneous PT-141 in healthy men and men who reported an inadequate response to sildenafil. Erectile response was statistically significant at both studied doses in the erectile-dysfunction crossover group. These were small, early studies, and the men’s program did not produce an approved indication. The route also differed across the two papers, which is why the historical intranasal findings should not be treated as evidence for any current nasal product; PT-141 nasal spray examines that gap.

PT-141 and kisspeptin answer different questions

PT-141 and kisspeptin both appear in sexual-health care, but evidence for one cannot be borrowed for the other. PT-141 is a melanocortin-receptor agonist with phase 3 HSDD trials. Kisspeptin sits in reproductive-hormone signaling and has its own smaller human research program around desire and brain response. What kisspeptin does explains that separate evidence. A prescriber has to match the compound to the clinical question rather than treating the two as interchangeable libido products.

What PT-141 is not shown to do

PT-141 has not been shown to improve every part of sexual function or address every cause of low desire. RECONNECT did not establish an increase in the number of satisfying sexual events. The early male trials do not establish a durable treatment benefit, and neither they nor the women’s trials make PT-141 a general sexual-performance enhancer.

The FDA label for Vyleesi limits the indication to acquired, generalized HSDD in premenopausal women. It says Vyleesi is not indicated for postmenopausal women, men, or enhancement of sexual performance. That boundary describes the evidence behind the branded product; it does not turn the smaller studies in other groups into phase 3 proof.

Benefit also cannot be separated from tolerability. Blood-pressure effects, nausea, medication interactions, pregnancy considerations, and cardiovascular history can change the risk-benefit decision. PT-141 side effects covers those questions rather than compressing them into a footnote here.

The compounded distinction and the clinical decision

As of September 2026, Promise’s PT-141 is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA’s current Vyleesi record lists a prescription bremelanotide autoinjector under NDA 210557, originally approved on June 21, 2019. The branded product and an individually prescribed compounded formulation are not the same finished product.

Regulatory status is one input into care, not the whole decision. A licensed provider may still prescribe a compounded formulation when clinically appropriate—that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.